In addition, CA-MSCs derived from cervical cancer patients were also shown to prevent antigen-specific CD8+ T lymphocytes from destroying CaSki cells in vitro, a human cervical cancer cell line (106). This evidence concerns the gene CD8A and cervical carcinoma.